Cullinan Oncology IPO

1/7/2021

IPO

$249,900,000

Per the firm's most recent regulatory filing, it plans to use the net proceeds as follows:approximately $45.0 million to $55.0 million to complete the Phase 1/2a trial of CLN-081, as well as to fund the initiation of a later stage trial in treatment experienced NSCLC patients with EGFRex20ins mutations;approximately $50.0 million to $60.0 million to advance CLN-049 and CLN-619 into Phase 1/2a trials for patients with r/r AML and advanced solid tumors, respectively;approximately $40.0 million to $50.0 million to advance CLN-617 and CLN-978 through IND-enabling studies and, assuming success of those studies and subject to FDA review of an IND submission, to initiate Phase 1/2a trials with those programs; andthe remaining proceeds, if any, for the continued advancement of our pipeline, including Jade and Opal, milestones for previously in-licensed programs, the identification and advancement of additional programs and development candidates, hiring of additional personnel, and costs of op

Publicly-held

Biopharmaceutical

1 Main St. 520
Cambridge, MA 02142
USA

Undisclosed

Cullinan (Nasdaq: CGEM) was formed to capitalize on the latest scientific breakthroughs by advancing a dynamic portfolio of innovative, early-stage assets. We develop both internally generated and externally sourced cancer therapeutics through a novel, cost efficient business model.